Profile data is unavailable for this security.
About the company
Pacific Biosciences of California, Inc. is a life science technology company. It is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding (SBB) short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. It has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which accurately detects the nucleotide sequence and epigenetic status of individual DNA molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.
- Revenue in USD (TTM)200.52m
- Net income in USD-306.74m
- Incorporated2000
- Employees796.00
- LocationPacific Biosciences of California Inc1305 O'brien DriveMENLO PARK 94025United StatesUSA
- Phone+1 (650) 521-8000
- Fax+1 (302) 636-5454
- Websitehttps://www.pacb.com/
More ▼
Mergers & acquisitions
| Acquired company | PACB:NSQ since announced | Transaction value |
|---|---|---|
| Apton Biosystems Inc | -87.33% | 110.00m |
Data delayed at least 15 minutes, as of May 01 2024 21:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioventus Inc | 502.76m | -122.57m | 313.50m | 970.00 | -- | 1.76 | -- | 0.6236 | -1.97 | -2.93 | 8.06 | 2.25 | 0.4552 | 2.14 | 4.10 | 448,889.30 | -14.34 | -- | -18.91 | -- | 62.87 | 70.26 | -31.51 | -9.18 | 0.9443 | 0.3731 | 0.6354 | -- | 18.85 | 11.89 | -919.12 | -- | -- | -- |
| Tactile Systems Technology Inc | 274.42m | 28.52m | 327.17m | 992.00 | 11.59 | 1.68 | 9.33 | 1.19 | 1.19 | 1.19 | 11.90 | 8.20 | 1.02 | 6.02 | 5.60 | 276,636.10 | 10.63 | 0.9015 | 13.23 | 1.09 | 49.95 | 49.10 | 10.39 | 0.8309 | 2.99 | -- | 0.1308 | 0.00 | 11.20 | 13.81 | 259.60 | 33.91 | -23.62 | -- |
| CVRx Inc | 39.30m | -41.20m | 334.95m | 200.00 | -- | 4.26 | -- | 8.52 | -1.99 | -1.99 | 1.89 | 3.64 | 0.3272 | 0.6974 | 6.02 | 196,475.00 | -34.31 | -- | -36.75 | -- | 84.08 | -- | -104.85 | -- | 12.86 | -23.96 | 0.2779 | -- | 74.89 | -- | 0.5528 | -- | -- | -- |
| Zynex Inc | 184.32m | 9.73m | 350.27m | 1.10k | 40.98 | 7.95 | 25.11 | 1.90 | 0.2677 | 0.2677 | 5.10 | 1.38 | 1.45 | 2.86 | 5.96 | 167,565.50 | 7.68 | 14.58 | 9.11 | 17.52 | 79.38 | 79.62 | 5.28 | 10.44 | 4.03 | 9.85 | 0.5581 | -- | 16.54 | 42.01 | -42.91 | 0.3741 | 2.19 | -- |
| Surmodics Inc | 138.20m | 5.52m | 365.72m | 376.00 | 65.69 | 2.99 | 25.66 | 2.65 | 0.3911 | 0.3911 | 9.82 | 8.58 | 0.7897 | 2.10 | 7.05 | 367,561.20 | 3.15 | -1.85 | 3.49 | -2.18 | 79.38 | 82.93 | 3.99 | -2.98 | 3.97 | 5.84 | 0.1942 | -- | 32.65 | 10.27 | 94.37 | -- | -27.02 | -- |
| Neuropace Inc | 65.42m | -32.96m | 373.07m | 171.00 | -- | 17.50 | -- | 5.70 | -1.28 | -1.28 | 2.53 | 0.7423 | 0.590 | 1.65 | 6.61 | 382,578.90 | -29.72 | -- | -33.88 | -- | 73.56 | -- | -50.38 | -- | 5.02 | -4.97 | 0.7339 | -- | 43.72 | -- | 30.00 | -- | -- | -- |
| MaxCyte Inc | 41.29m | -37.92m | 378.96m | 143.00 | -- | 1.63 | -- | 9.18 | -0.3675 | -0.3675 | 0.3998 | 2.23 | 0.1488 | 0.4558 | 4.27 | 288,727.30 | -13.67 | -13.18 | -14.54 | -14.33 | 88.51 | 88.79 | -91.85 | -62.96 | 9.97 | -- | 0.00 | -- | -6.72 | 19.89 | -60.89 | -- | 39.13 | -- |
| Nevro Corp | 425.17m | -92.21m | 388.09m | 1.22k | -- | 1.31 | -- | 0.9128 | -2.57 | -2.57 | 11.82 | 8.06 | 0.6868 | 1.24 | 5.37 | 349,937.40 | -14.90 | -13.64 | -17.15 | -16.68 | 68.22 | 68.54 | -21.69 | -20.67 | 4.94 | -- | 0.4191 | -- | 4.63 | 1.88 | -3,172.74 | -- | 0.9012 | -- |
| Pulse Biosciences Inc | 0.00 | -42.21m | 407.01m | 56.00 | -- | 9.16 | -- | -- | -0.8936 | -0.8936 | 0.00 | 0.8044 | 0.00 | -- | -- | 0.00 | -61.61 | -93.21 | -67.89 | -104.99 | -- | -- | -- | -12,332.25 | -- | -- | 0.00 | -- | -100.00 | -- | 27.85 | -- | -15.20 | -- |
| ZimVie Inc | 457.43m | -56.05m | 413.76m | 2.60k | -- | 1.01 | -- | 0.9045 | -2.12 | -14.87 | 17.33 | 15.12 | 0.3213 | 1.07 | 3.91 | 175,935.80 | -3.94 | -- | -4.56 | -- | 63.48 | 65.51 | -12.25 | -8.73 | 2.32 | -0.5562 | 0.5541 | -- | -1.26 | -16.08 | -19.50 | -- | -23.70 | -- |
| Pacific Biosciences of California Inc | 200.52m | -306.74m | 442.12m | 796.00 | -- | 0.6299 | -- | 2.20 | -1.21 | -1.21 | 0.7907 | 2.62 | 0.1142 | 2.70 | 7.24 | 251,910.80 | -17.46 | -16.19 | -19.45 | -17.81 | 28.03 | 37.35 | -152.97 | -136.21 | 7.21 | -22.45 | 0.5601 | -- | 56.29 | 20.59 | 2.39 | -- | 36.68 | -- |
| Orthofix Medical Inc | 746.64m | -151.40m | 486.29m | 1.63k | -- | 0.8070 | -- | 0.6513 | -4.15 | -4.15 | 20.33 | 16.11 | 1.08 | 1.62 | 7.08 | 456,940.60 | -21.88 | -8.88 | -26.68 | -10.96 | 65.13 | 72.37 | -20.28 | -9.28 | 1.20 | -16.11 | 0.1595 | -- | 62.06 | 10.51 | -666.60 | -- | 30.01 | -- |
| Iradimed Corp | 65.56m | 17.19m | 514.24m | 148.00 | 30.07 | 7.20 | 28.64 | 7.84 | 1.35 | 1.35 | 5.15 | 5.64 | 0.738 | 1.69 | 5.14 | 442,988.50 | 19.35 | 13.16 | 22.51 | 14.58 | 76.50 | 76.55 | 26.22 | 21.46 | 3.87 | -- | 0.00 | 68.13 | 23.00 | 16.59 | 34.02 | 22.22 | 97.77 | -- |
| Nano-X Imaging Ltd | 9.91m | -60.78m | 517.70m | 164.00 | -- | 2.65 | -- | 52.27 | -1.08 | -1.08 | 0.1757 | 3.38 | 0.0419 | -- | 8.05 | 60,396.34 | -25.72 | -30.98 | -28.14 | -35.10 | -66.55 | -- | -613.59 | -1,527.24 | 5.56 | -- | 0.0175 | -- | 15.47 | -- | 46.33 | -- | 114.35 | -- |
| Embecta Corp | 1.12bn | 55.30m | 583.27m | 2.20k | 10.55 | -- | 6.49 | 0.5197 | 0.9598 | 0.9598 | 19.47 | -13.78 | 0.9296 | 2.57 | 19.35 | 510,181.80 | 4.58 | -- | 6.44 | -- | 66.55 | -- | 4.93 | -- | 1.75 | 1.67 | 1.94 | -- | -0.7703 | -- | -68.52 | -- | -- | -- |
| SI-Bone Inc | 138.89m | -43.34m | 585.58m | 344.00 | -- | 3.43 | -- | 4.22 | -1.13 | -1.13 | 3.62 | 4.16 | 0.716 | 1.57 | 6.52 | 403,738.40 | -22.34 | -27.88 | -25.24 | -30.94 | 78.78 | 85.03 | -31.20 | -51.09 | 8.15 | -- | 0.1756 | -- | 30.52 | 20.19 | 29.25 | -- | 52.62 | -- |
Data as of May 01 2024. Currency figures normalised to Pacific Biosciences of California Inc's reporting currency: US Dollar USD
60.10%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| ARK Investment Management LLCas of 31 Mar 2024 | 33.29m | 12.42% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 26.20m | 9.78% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 19.81m | 7.39% |
| Madrone Advisors LLCas of 31 Dec 2023 | 17.59m | 6.57% |
| Nikko Asset Management Americas, Inc.as of 31 Dec 2023 | 13.20m | 4.93% |
| Nikko Asset Management Co., Ltd.as of 31 Mar 2024 | 12.82m | 4.79% |
| Morgan Stanley & Co. LLCas of 31 Dec 2023 | 10.50m | 3.92% |
| Newton Investment Management North America LLCas of 31 Mar 2024 | 10.15m | 3.79% |
| Jackson Square Partners LLCas of 31 Dec 2023 | 9.70m | 3.62% |
| T. Rowe Price Investment Management, Inc.as of 31 Dec 2023 | 7.75m | 2.89% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
